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Abstract
Background: Gastric cancer continues to be one of the deadliest cancers in the world and therefore identification of new
drugs targeting this type of cancer is thus of significant importance. The purpose of this study was to identify and validate a
therapeutic agent which might improve the outcomes for gastric cancer patients in the future.
Methodology/Principal Findings: Using microarray technology, we generated a gene expression profile of human gastric
cancer–specific genes from human gastric cancer tissue samples. We used this profile in the Broad Institute’s Connectivity
Map analysis to identify candidate therapeutic compounds for gastric cancer. We found the histone deacetylase inhibitor
vorinostat as the lead compound and thus a potential therapeutic drug for gastric cancer. Vorinostat induced both
apoptosis and autophagy in gastric cancer cell lines. Pharmacological and genetic inhibition of autophagy however,
increased the therapeutic efficacy of vorinostat, indicating that a combination of vorinostat with autophagy inhibitors may
therapeutically be more beneficial. Moreover, gene expression analysis of gastric cancer identified a collection of genes
(ITGB5, TYMS, MYB, APOC1, CBX5, PLA2G2A, and KIF20A) whose expression was elevated in gastric tumor tissue and
downregulated more than 2-fold by vorinostat treatment in gastric cancer cell lines. In contrast, SCGB2A1, TCN1, CFD, APLP1,
and NQO1 manifested a reversed pattern.
Conclusions/Significance: We showed that analysis of gene expression signature may represent an emerging approach to
discover therapeutic agents for gastric cancer, such as vorinostat. The observation of altered gene expression after
vorinostat treatment may provide the clue to identify the molecular mechanism of vorinostat and those patients likely to
benefit from vorinostat treatment.
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Introduction
Gastric cancer is the fourth most common cancer and the
second leading cause of cancer death in the world [1], with an
overall survival of about 10 months [2–4]. Treatment for gastric
cancer may include chemotherapy, surgery and radiation therapy.
Unfortunately, current chemotherapy-based treatments for ad-
vanced gastric cancer demonstrate disappointing results [2–4].
Indeed, complete remissions are rare or only last very shortly.
Several targeted agents that confer survival advantages in other
cancer types have been under investigation in gastric cancer.
While some early clinical studies using vascular endothelial growth
factor receptor (VEGFR) and epithelial growth factor receptor
(EGFR) -1 inhibitors, such as cetuximab and bevacizumab, have
shown somewhat activity, there is rarely an actual survival benefit
for the patients [5,6]. One of the reasons may be that these studies
did not select patients according to the presence of biomarkers.
Recently, the Trastuzumab for Gastric Cancer (ToGA) trial noted
that the addition of trastuzumab to chemotherapy led to a
statistically significant improvement in progression-free survival
(PFS) and overall survival (OS) of the approximately 20% of
patients with disseminated gastric and gastroesophageal (GE)
junction tumors overexpressing HER2 [7]. This emphasizes the
need for targeted biological therapy and the search for biomarkers
to select patients for clinical trials which may benefit survival.
Despite some evidence of potential targets, including HER2 [8,9],
the efficacy of these biologically targeted therapies is not known
and there is a lack of a standard targeted therapy for gastric
cancer. Owing to the biological heterogeneity of gastric cancers, it
is unlikely that there is a single ‘magic bullet’ cure. Molecular
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markers will be thus important in the future to predict patients’
outcomes and tailoring treatments according to individual biology.
In the search for biomarkers, gene expression signature analysis
has been used in diverse applications, such as for elucidating the
mechanisms of biological pathways [10], classifying subtypes of a
disease [11], predicting cancer prognosis [12] and profiling gene
expression in response to specific drugs [13,14]. Gene expression
signature analysis can be done by using The Broad Institute’s
Connectivity Map (http://www.broadinstitute.org/cmap). The
Connectivity Map aims to generate a map that links gene
expression patterns associated with disease to corresponding
patterns produced by drug candidates and genetic manipulations
[15,16]. This systems approach allows compounds to be screened
against genome-wide disease signatures, rather than a preselected
set of target genes. Drugs are paired with diseases using
sophisticated pattern-matching methods with a high level of
resolution and specificity. Although it leaves many open questions,
the Connectivity Map has shown that genomic signature analysis
can be used to recognize drugs with common mechanisms of
actions, discover unknown mechanisms of action and identify
potential new therapeutics [15,16].
The purpose of this study was to identify potential new
therapeutics for the treatment of gastric cancer. To do this, we
first analyzed the genomic signature of human gastric cancer. The
resultant gastric cancer gene signature was then used in silico by
employing Connectivity Map analysis to identify therapeutic
agents that could potentially be effective against this type of
cancer. We further validated the top targeting drug for its efficacy
in gastric cancer cell lines. We found that vorinostat, as a potential
new drug, induced both apoptosis and autophagy in gastric cancer
cells. Together, this study demonstrates that the Connectivity Map
analysis can be used for the identification of therapeutic agents
that may be successful in the treatment of a subset of gastric
cancers.
Methods
Analysis of microarray data
For the Connectivity Map analysis, we used the microarray data
of 65 gastric cancer patients, including 65 cancers and 19 normal
gastric tissues, which were obtained from our previous work,
Yonsei data [17]. Tumor specimens were collected from gastric
cancer patients undergoing gastrectomy as a primary treatment.
Tissue samples were examined by pathologists at the time of
collection and stored in 280uC at the tissue bank until the start of
the experiment. Total RNA was extracted from the fresh-frozen
tissues by using a mirVana RNA isolation labeling kit (Ambion,
Inc.). Primary microarray data is available in NCBI’s Gene
Expression Omnibus public database (microarray platform,
GPL6884; microarray data, GSE 13861). Another gene expression
profile was obtained from 69 gastric tissue samples, including 38
cancer and 31 non cancer stroma, of the Stanford Microarray
Database (http://smd.stanford.edu, GSE13911), Stanford data.
Gastric cancer-specific genes were selected by BRB-ArrayTools
version 3.6.1 (Biometric Research Branch, National Cancer
Institute, Bethesda, MD). Class comparison using two sample t-
test (significance ,0.001, 10,000 random permutation) identified
gastric cancer specific genes and genes whose mean expression
intensities were altered by at least two-fold compared to mean
normal tissue gene expression were selected.
Connectivity Map analysis
To identify potential drugs targeting gastric cancer, the gene
lists of top 500 up regulated and the top 500 down regulated genes
from the gastric cancer-specific genes were used (Table S1). The
Connectivity Map analysis was conducted through the Web
interface (http://www.broadinstitute.org/cmap) using version,
build 02, which contains more than 7,000 expression profiles
representing effects of 1,309 compounds on several cultured
human cells [15,16]. The Connectivity map shows functional
connections between drugs, genes and disease. Drugs that produce
disease-mimicking gene signatures can help identify pathways that
represent potential therapeutic targets for that disease. Conversely,
drugs that induce a ‘reverse’ signature, i.e. changes in gene
expression in a direction opposite to that observed in the disease
state, could represent new therapeutic agents. Candidate agents
against a specific disease can be recognized by applying disease
specific gene expression profile to the Connectivity Map analysis.
We selected candidate drugs for validation in vitro on the basis of
the connectivity score, correlation, and P-value.
Chemicals and cell culture
Vorinostat was obtained from Merck and prepared as a stock
solution in dimethylsulfoxide (DMSO). Chloroquine and bafilo-
mycin A1 (Sigma) were dissolved in respectively water and
DMSO. Human gastric cancer cell lines AGS, NCI-N87, and
KATO-III were obtained from the American Type Culture
Collection and were maintained according to their recommenda-
tions. Cells were cultured in RPMI 1640 supplemented with 10%
fetal bovine serum, 100 U penicillin, and 100 mg/ml streptomycin
at 37uC in 5% CO2.
Cell growth, viability and cell cycle assays
For the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay, MTT was dissolved in PBS at 5 mg/ml.
About 56103 cells were seeded in 96-well plates and allowed to
attach overnight. The culture medium was then replaced with
fresh medium containing the indicated concentrations of vorino-
stat or DMSO. After 72 h, 20 ml of MTT solution was added, and
the plates were incubated at 37uC for 4 h. After incubation, 100 ml
of DMSO was added to dissolve the formazan, and absorbance
was read at 570 nm using a spectrophotometric microplate reader
(Vmax kinetic microplate reader, Molecular Devices). The
experiments were done in triplicate.
For crystal violet staining, cells were treated for 12 h, the
medium was removed, and the cells were washed with PBS and
then incubated for 30 min with 0.5% crystal violet (in 20%
methanol and 80% double-distilled water). The cells were then
washed three times with PBS. The remaining crystal violet was
extracted in acetic acid for 5 min, and absorbance was measured
at 595 nm using a spectrophotometric microplate reader.
To determine cell viability, cells were incubated with vorinostat
for 72 h. Adherent cells were then detached from culture plates by
trypsinization and combined with floating cells, centrifuged and
suspended in 500 ml of propidium iodide (PI)-exclusive solution
(not cell membrane penetrating) for 15 min at 4uC. Stained cells
were monitored by flow cytometry (Beckman Coulter Cytomics
FC 500).
For cell cycle analysis, cells were incubated with vorinostat for
24 h, collected and suspended in 500 ml of hypotonic solution
(0.1% sodium citrate, 0.1% Triton X-100, 100 mg/ml RNase and
50 mg/ml PI) for 15 min at 4uC. PI-stained cells were monitored
by flow cytometry. Cell cycle was analyzed by MultiCycle AV
software.
RNA isolation and microarray experiments
RNA isolation and microarray experiments were performed
according to the protocol as previously described [17]. Total RNA
Vorinostat for Gastric Cancer Treatment
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was extracted from gastric cancer cell lines with or without
vorinostat treatment using a mirVana RNA isolation kit (Ambion,
TX, USA). The integrity of the large RNA fraction was
determined with an Experion Bioanalyzer (Bio-Rad, CA, USA)
as a surrogate for mRNA quality control. Total RNA was labeled
and hybridized with human HT12 v.3 expression BeadChips
according to the manufacturer’s protocols (Illumina, CA, USA).
After the BeadChips were scanned with an Illumina BeadArray
Reader, the microarray data were normalized using the quantile
normalization method in the Linear Models for Microarray Data
package in the R language environment [18]. The expression level
of each gene was transformed into a log2 base before further
analysis. Cluster analysis was done with Cluster and Treeview
[19].
Western blot analysis
Cells were scraped in medium and spun down, and proteins
were isolated using lysis buffer (50 mM HEPES, 150 mM NaCl,
1 mM EGTA and 10 mM sodium pyrophosphate (pH 7.4))
containing 100 mM NaF, 10% glycerol, 1.5 mM MgCl2, 1%
Triton X-100 and protease inhibitor (Roche). Extracts were
incubated on ice for 20 min and spun down at 20800 g for
20 min. Protein concentration was determined using BCA
protein assay reagent (Pierce). Equal amounts of protein from
each sample were separated by electrophoresis through SDS-
PAGE and transferred to Hybond-C Super membrane (Amer-
sham Pharmacia Biotech). Membranes were blocked for 1 h at
room temperature in Tris-buffered saline containing 0.1%
Tween-20 and 5% nonfat dry milk. Membranes were incubated
overnight at 4uC with primary antibody diluted in 5% nonfat
dry milk or 5% BSA in 16 Tris-buffered saline plus 0.1%
Tween-20. Antibodies to LC3 (Novus Biologicals), active
caspase-3 (Epitomics) and p62 (BD Biosciences) were used.
Antibodies to a-tubulin and beclin-1 were from Cell Signaling
Technology; antibody to b-actin was from Sigma. Membranes
were then washed and incubated for 1 h at room temperature
with peroxidase-conjugated secondary antibody (Cell Signaling
Technology). Protein bands were visualized using enhanced
chemiluminescence as described by the manufacturer (GE
Healthcare).
siRNA transfection
The siRNA target sequence for beclin-1, nontargeting
siRNA (Risc Free) and Dharmafect 1 were purchased from
Dharmacon. Cells were seeded in 10-cm dishes and transfected
with siRNA 24 h later according to the manufacturer’s
protocol. The next day, cells were trypsinized and seeded in
6-cm or 96-well plates to obtain the same transfection
efficiency. Protein expression levels were determined by
western blot analysis.
Transmission electron microscopy
Samples were fixed with a solution containing 3% gluter-
aldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer,
pH 7.3, for 1 hour. After fixation, the samples were washed and
treated with 0.1% Millipore-filtered cacodylate buffered tannic
acid, postfixed with 1% buffered osmium tetroxide for 30 min,
and stained en bloc with 1% Millipore-filtered uranyl acetate.
The samples were dehydrated in increasing concentrations of
ethanol, infiltrated, and embedded in LX-112 medium. The
samples were polymerized in a 70uC oven for 2 days. Ultrathin
sections were cut in a Leica Ultracut microtome (Leica,
Deerfield, IL), stained with uranyl acetate and lead citrate in a
Leica EM stainer, and examined in a JEM 1010 transmission
electron microscope (JEOL, USA, Inc., Peabody, MA) at an
accelerating voltage of 80 kV. Digital images were obtained
using AMT Imaging System (Advanced Microscopy Techniques
Corp, Danvers, MA).
Table 1. Baseline characteristics of the gastric cancer patients
(Yonsei data).
Characteristics N=65
Age (yr)
Median (range) 63 (32–83)
Sex (%)
Male: Female 46 (71): 19 (29)
Subsite of tumor (%)
Cardia 5 (8)
Body 24 (37)
Antrum 32 (49)
Diffuse 4 (6)
Histologic type of tumor (%)
Intestinal 23 (35)
Diffuse 32 (49)
Mixed 10 (16)
Cancer stage, TNM class (%)
I 12 (18)
II 11 (17)
III 26 (40)
IV 16 (25)
Adjuvant chemotherapy (%)
No: Yes 16 (25): 49 (75)
doi:10.1371/journal.pone.0024662.t001
Table 2. Top 5 candidate drugs of gastric cancer from Connectivity Map analysis.
Rank
Yonsei Data
(GSE31861)
Mean
correlation (r) p-value
Stanford Data
(GSE13911)
Mean
correlation (r) p-value
1 vorinostat 20.716 ,0.00001 vorinostat 20.714 ,0.00001
2 trichostatin A 20.643 ,0.00001 trichostatin A 20.653 ,0.00001
3 tanespimycin 20.539 ,0.00001 tanespimycin 20.527 ,0.00001
4 trifluoperazine 20.538 ,0.00001 LY-294002 20.52 0.00002
5 LY-294002 20.45 ,0.00001 0297417-0002B 20.815 0.00052
doi:10.1371/journal.pone.0024662.t002
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Figure 1. In vitro therapeutic efficacy of vorinostat in gastric cancer cell lines. (A) MTT assays were performed after incubation of AGS,
KATO-III, and NCI-N87 with the indicated concentrations of vorinostat for 72 hrs. (B) Change of cell cycle by vorinostat was assessed by fluorescence-
activated cell sorting (FACS) analysis of PI stained cells treated with 5 mM vorinostat for 24 hrs. (C) Viability test using PI exclusive solution. AGS and
KATO-III cells were treated with 5 mM vorinostat for 72 hrs and assessed by FACS. In representative plot, dead cells were manifested as dots with low
forward scatter and high side scatter. (D) Western blot analysis of active caspase-3 from AGS and KATO-III gastric cancer cells without or with 5 mM
vorinostat treatment. Cell lysates were analyzed at the indicated time points. Actin was used as a loading control. *, P,0.05. In the bar graph, data
represent mean+SD (standard deviation).
doi:10.1371/journal.pone.0024662.g001
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Results
Gene expression signature of gastric cancer
Table 1 represents the characteristics of the patients from
Yonsei data [17]. Gastric cancers were mostly located in distal
stomach and stage III/IV. Using the gene expression microarray
data of those patients, we found 3,360 tumor-specific genes whose
mean expression intensities were altered by at least two-fold
compared to mean normal tissue gene expression (P,0.001,
Figure S1). This set of 3,360 genes (i.e. gastric cancer-specific
signature) was used for further in silico screening for potential
therapeutic drugs for gastric cancer.
Connectivity Map analysis identifies potential drugs
targeting gastric cancer
To identify potential drugs targeting gastric cancer, the gastric
cancer specific signature was used as input query into Connectivity
Map as described in the ‘Method’ section. We specifically looked
for compounds that had a signature inversely correlated with the
gastric cancer-specific signature and identified multiple drugs
which are summarized in Table 2. The ranking of candidate
agents was established based on inverse correlation value and p-
value. Table 2 (columns 2–4) shows the highest ranked compounds
from Yonsei data. Connectivity Map analysis revealed that histone
deacetylase (HDAC) inhibitors, including vorinostat and trichos-
tatin A represent potential candidates for targeting gastric cancer.
The phosphatidylinositol-3-kinase inhibitor LY294002, the phe-
nothiazine trifluoperazine and the heat shock protein inhibitor
tanespimycin were also identified as candidate target agents for
gastric cancer. Next, we validated our findings by using an
independent set of gene expression profile data from Stanford
Microarray Database (Table 2; Stanford Data; columns 5–7).
Connectivity Map analysis of this data set confirmed vorinostat as
the top ranked candidate. In conclusion, Connectivity Map
analysis identified vorinostat as a potential therapeutic agent for
gastric cancer.
Vorinostat shows therapeutic efficacy in vitro in gastric
cancer cell lines
To evaluate the therapeutic efficacy of vorinostat, we assessed
the growth of established gastric cancer cell lines (AGS, KATO-
III, and NCI-N87) after 72 h vorinostat treatment using MTT
assay. Compared with untreated cells, vorinostat significantly
inhibited cell viability in a dose-dependent manner in all gastric
cancer cell lines (Figure 1A). We confirmed the reduction in cell
viability by cell cycle analysis of AGS and KATO-III cancer cells.
We showed that treatment with vorinostat (5 mM) for 24 h
induced a marked increase in the sub-G1 proportion of AGS cells
compared with control (2.360.07% vs 39.260.99%, respectively;
P,0.01), indicating the induction of cell death (Figure 1B). In
contrast, the sub-G1 proportion of vorinostat treated KATO-III
cells was not affected (Figure 1B), whereas the proportion of G2/
M cells increased significantly (21.461.91% vs. 29.360.35%;
P=0.044), indicative for cell cycle arrest. We further tested cell
viability using PI-exclusion. We treated AGS and KATO-III cells
with 5 mM vorinostat for 72 h and assessed them by flow
cytometry (Figure 1C). The amount of dead cells, which have
low forward scatter and high side scatter, was significantly
Figure 2. Hierarchical Clustering Gene expression analysis of
gastric cancer cell lines after vorinostat treatment. (A) Unsuper-
vised hierarchical clustering of gene expression data from AGS and
KATO III before and after 5 mM vorinostat treatment for 48 hours. Genes
with an expression level that has at least 2-fold difference relative to
median value across cell lines in at least 2 arrays were selected for
hierarchical clustering analysis (3,646 gene features). (B) Supervised
hierarchical clustering with autophagy related genes (149 probes) of
AGS and KATO III after vorinostat treatment.
doi:10.1371/journal.pone.0024662.g002
Figure 3. Autophagy induction by vorinostat treatment in gastric cancer cells. (A) AGS and KATO-III were treated with 5 mM vorinostat for
the indicated time points. Protein levels of LC3 and p62 were analyzed by immunoblot analysis. Actin was used as a loading control. p62 levels were
measured by densitometric analysis of the western blots and compared to actin levels. p62 levels of untreated AGS and KATOIII cells were considered
as 1. (B) AGS cells were treated for 12 h with 5 mM vorinostat with or without 50 nM bafilomycin A1 (BafA1). Cell lysates were analyzed by
immunoblot analysis for LC3 and actin.
doi:10.1371/journal.pone.0024662.g003
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increased in AGS cells (12.464.3% vs. 79.465.7%), and also in
KATO-III cells, compared to control cells (8.760.6% vs.
46.862.1%). We finally analyzed the induction of apoptosis after
vorinostat treatment in AGS and KATO-III gastric cancer cell
lines using immunoblot. Vorinostat increased apoptosis, as
assessed by caspase-3 cleavage, in AGS cells and to a lesser extent
in KATO-III cells (Figure 1D).
In summary, these data indicate that vorinostat has antiprolif-
erative effect on gastric cancer cell lines by inducing apoptosis in
AGS cells and G2/M cell cycle arrest in KATO-III cells.
Global gene expression analysis of gastric cancer cell
lines AGS and KATO-III after vorinostat treatment
To analyze the effect of vorinostat on global gene expression,
AGS and KATO-III gastric cancer cells were treated with 5 mM
vorinostat for 48 hours and microarray analysis was performed.
Unsupervised cluster analysis of microarray data after vorinostat
treatment showed that AGS and KATO-III cells clustered with
the same cell line regardless to vorinostat treatment (Figure 2A).
Because autophagy has been reported to have a role in vorinostat-
induced effects in other cancers [20,21], we conducted supervised
analysis of the autophagy-related gene set (80 genes and 149
probes; Table S2). Vorinostat-treated gastric cancer cell lines were
clustered together (Figure 2B), indicating that induction of
autophagy is an important property of vorinostat in gastric cancer
lines.
Inhibition of autophagy enhances vorinostat efficacy in
gastric cancer cells
Given that autophagy may have a role in both cancer cell
survival and cancer cell death after drug treatment [22,23], we
further evaluated the contribution of this process to the effect of
vorinostat on gastric cancer cell lines. We functionally evaluated
this process by immunoblot analysis of the autophagy marker
microtubule-associated protein 1 light chain 3 (LC3). Vorinostat-
treated KATO-III cells, and to a lesser extent AGS cells, showed a
clear accumulation of the faster-migrating lipidated form of LC3
(LC3-II) (Figure 3A). Accumulation of LC3-II may result from
either upregulation of autophagosome formation or blockage of
autophagic degradation of LC3-II [24,25]. We therefore analyzed
vorinostat-treated cells for p62 degradation, a marker of
autophagic flux [24], and we observed a decrease in p62 protein
levels in vorinostat treated cells compared to the time matched
untreated cancer cells (Figure 3A). In addition, cotreatment of
vorinostat with bafilomycin A1 (BafA1), an inhibitor of autopha-
gosome-lysosome fusion, further increased LC3-II accumulation
(Figure 3B), compatible with vorinostat inducing autophagic flux
rather than blocking the degradative capacity of autophagoly-
somes. Electron microscopy (EM) is a sensitive, quantitative and
definitive method for detection of autophagy [24]. Consistent with
the western blot data, EM analysis showed that vorinostat
markedly increased autophagosome formation in AGS cells
(Figure 4B and B’) compared to control cells (Figure 4A and A’).
To investigate whether the accumulation of autophagosomes
protects cells against the cellular stress elicited by vorinostat, we
inhibited the autophagy process using the pharmacological
inhibitor chloroquine and small interfering RNA (siRNA) against
beclin-1. Addition of chloroquine to vorinostat-treated AGS and
KATO-III cells resulted in a dose-dependent decrease in viability
(Figure 5A). The reduction in viability was confirmed in KATO-
III cells treated with beclin-1 siRNA (Figure 5B). Together, the
data suggest that inhibition of vorinostat-induced autophagy may
improve the efficacy of vorinostat treatment of gastric cancer cells.
Vorinostat changes gene signature in human gastric
cancer cells
To understand the effects of vorinostat on gene expression in
gastric cancer cell lines, we conducted microarray analysis of
vorinostat treated AGS and KATO-III gastric cancer cell lines
(Fig. 2). Our analysis revealed significant genomic differences
between untreated and vorinostat-treated gastric cancer cells (AGS
and KATO-III). After vorinostat treatment, the expression of 1014
genes was increased and the expression of 760 genes was decreased
in the AGS cell line. In KATO-III cell line, 164 genes were up and
191 genes were down regulated (two-fold difference; P,0.001).
Vorinostat altered significantly the expression of 140 genes in both
AGS and KATO-III cell lines (vorinostat specific gene signature).
The genes which were most altered after vorinostat treatment were
identified as SPANXA1, SPANXA2, VGF, DHRS2, ENTPD8,
PNPLA7, STX1A, ARRDC4, KRT13, PRPH, NEU1, TXNIP, CCK
(.4-fold up-regulation) and MUC1, IFITM1, ANKRD37 (.4-fold
down-regulation).
Next, we intended to identify biomarker candidates which can
predict vorinostat sensitivity of human gastric cancer patients.
Therefore, we combined the set of altered genes in vorinostat treated
gastric cancer cell lines (vorinostat specific gene signature) and the two
human gastric cancer signatures generated from the Yosei and
Stanford data using Venn diagram analysis. We found that the relative
expression levels of 12 genes were reversed by vorinostat treatment
(Figure 6). Of these 12 genes, 7 genes highly expressed in gastric cancer
tissues were down-regulated (ITGB5, TYMS, MYB, APOC1, CBX5,
PLA2G2A, KIF20A) and 5 low-expressed genes were up-regulated after
vorinostat treatment (SCGB2A1, TCN1, CFD, APLP1, NQO1 (Table 3).
Figure 4. Electron microscopy analysis of autophagy in AGS
cells. After 12 h treatment DMSO (A, A’) or with 5 mM vorinostat (B, B’)
(left panels, low magnification, scale bar: 2 mm), EM analysis was
performed. High magnification images of boxed areas with Av
depicting autophagic vacuoles (left panels, scale bar: 500 nm; N:
nucleus, M: mitochondria).
doi:10.1371/journal.pone.0024662.g004
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Discussion
Our results indicate that a global human gastric cancer gene
signature might be useful to find therapeutic agents that rather
target the genomic signature of gastric cancer instead of targeting
one or two specific genes. Using the Connectivity Map, we found
that HDAC inhibitors, such as vorinostat and trichostatin A, had
an inversely correlated gene signature compared to the gastric
cancer specific gene signature and therefore may be lead
therapeutic candidates for gastric cancer. In vitro evaluation of
the therapeutic efficacy of vorinostat revealed that this therapeutic
drug suppressed growth of different gastric cancer cell lines. Next
to its antiproliferative effects, vorinostat also upregulated autoph-
agy-specific genes. Inhibition of vorinostat-induced autophagy
resulted in a further reduction of viability. Moreover, combined
analysis of gastric cancer cell lines treated with vorinostat and
samples of gastric cancer patients showed that vorinostat altered
the expression levels of a set of twelve gastric cancer specific genes.
Figure 5. Effect of vorinostat-induced autophagy inhibition. (A) AGS and KATO-III cells were treated with 5 mM vorinostat and different
concentrations of chloroquine (CQ). Cell viability was assessed after 12 hours using crystal violet staining and control (Ctr) was set as 100%. (B)
KATO-III cells were transfected with siRNA against Beclin 1 (siBeclin1) or with non-targeting Risc Free siRNA or treated with Dharmafect I alone
(mock). siRNA efficiency was confirmed by western blot analysis of Beclin 1 and Risc Free as a control. a-tubulin was used to show equal loading
of proteins. Viability was measured after 12 hours vorinostat treatment using crystal violet staining. Viability of untreated control (Ctr) cells was
set as 100%. *, P,0.05.
doi:10.1371/journal.pone.0024662.g005
Figure 6. Change of gene expression signature after vorinostat treatment. Venn Diagram of genes selected by univariate test (two-sample
t-test). Genes were selected for p,0.001 between compared groups. The red circle (gene list A) represents gastric cancer specific genes from Yonsei
data. The blue circle (gene list B) represents gastric cancer specific genes from Stanford data. The yellow circle (gene list C) represents vorinostat
specific gene signature from both AGS and KATO-III cell lines (P,0.001, 2 fold change).
doi:10.1371/journal.pone.0024662.g006
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Our findings showed that HDAC inhibitors, vorinostat and
trichostatin A, were the top therapeutic candidates for gastric
cancer, which agrees with the concept that HDAC is overex-
pressed in gastric cancer tissues [26]. HDAC inhibitors have been
shown to increase acetylation of histones, therefore affecting gene
expression. These inhibitors manifest anticancer effects by
inducing the intrinsic and extrinsic apoptosis pathway [27,28],
blocking tumor angiogenesis [29], and inhibiting intracellular
stress response pathways [30]. Because HDAC inhibitors have
global effects on gene expression, they may affect as yet unrevealed
cellular processes [31,32]. In clinical settings, HDAC inhibitors
have been mostly applied to hematologic malignancies, but clinical
trials in solid tumors are ongoing. A recent study, supporting our in
vitro findings showed therapeutic efficacy of HDAC inhibitors on
human gastric cancer samples using the histoculture drug response
assay [33]. However, it remains to be unrevealed whether specific
molecular-defined subgroups can predict response or resistance to
HDAC inhibitors. In addition, the application of potentially useful
biomarkers still has several limitations [34].
The Connectivity Map remains difficult to evaluate until we
can assess the extent to which genomic signatures obtained from
in vitro experiments recapitulate the complexities of human
disease. Although the Connectivity Map contains more than
7000 expression profiles representing 1,309 compounds, its
approach still deals with some limitations such as the limited
amount of cell line data (MCF7, PC3, etc) and the ignorance of
microenvironmental influences from the human body [16]. In
addition, gene expression profiles derived from the treatment of
cultured human cells might not be correlated with in vivo
anticancer effect, due to the complex nature of cancer.
Moreover, the input of only a limited amount of genes is
allowed, which may bias the obtained results. Future studies
need to be addressed whether our results obtained through cmap
analysis can be confirmed in an in vivo gastric cancer model.
Despite these limitations, Connectivity Map analysis is a
potentially useful method for new functions for drugs, including
vorinostat, already in use in clinic for other purposes.
In vitro evaluation of therapeutic efficacy of vorinostat on gastric
cancer cell lines revealed that this therapeutic drug showed an
antiproliferative effect at physiological relevant doses (5 mM)
compatible with other publications: IC50 for AGS and KATO-
III has been shown to be respectively 2.9 mM and 5.9 mM [35].
Analysis of cell cycle (Figure 1B), cell viability and (Figure 1C)
apoptotic responses (Figure 1D) indicated that the effects of
vorinostat show a discrepancy in different gastric cancer cell lines,
inducing apoptosis in AGS cells and G2/M arrest in KATO-III
cells, respectively. The difference in genetic/mutational back-
ground of the cell lines may account for the discrepancy.
Microarray gene expression analysis comparing vorinostat-
treated and untreated gastric cancer cell lines indicated that this
drug induced autophagy, which is in agreement with previous
reports in other cancer cell lines [20,21]. As both induction and
inhibition of autophagy may have therapeutic benefits [22,23], we
further evaluated the role of autophagy in gastric cancer cells after
vorinostat treatment. Inhibiting autophagy using a well-known
antimalarial drug, chloroquine [21] and using siRNA against
beclin-1 resulted in a reduction in viability of gastric cancer cell
lines in the presence of vorinostat, suggesting autophagy is
activated as a protective survival response after vorinostat
treatment (Figure 5). Thus combining anticancer agents such as
vorinostat and inhibitors of autophagy could provide a therapeutic
advantage in the fight against gastric cancer.
To identify a vorinostat induced gene signature, we evaluated
the gene expression profiles of AGS and KATO-III cell lines after
vorinostat treatment. The expression of 1774 and 355 genes was
reversed (.2-fold, p,0.001) in AGS and KATO-III cell lines,
respectively. This suggests that the AGS cell line was more
vulnerable than KATO-III to vorinostat treatment in regard to
gene expression. This manifestation may explain the sensitivity of
AGS cells to vorinostat. We discovered that vorinostat significantly
changed the expression of a set of 140 genes in both AGS and
KATO-III cell lines. Our results confirm earlier studies showing
that that expression of MUC1 and TXNIP is reversed after
HDAC inhibitor treatment [36–38]. High MUC1 expression is
related to poor prognosis and carcinogenesis in gastric cancer [39].
Additionally, re-expression of TXNIP leads to cell growth arrest
and apoptosis in cancer [37].
To determine a vorinostat induced gene signature for human
gastric cancer, we combined the vorinostat induced cell line gene
signature with the human gastric cancer gene signature We found
that vorinostat altered expression levels (.2 fold) of only twelve
human gastric cancer specific genes, which can potentially explain
the mechanism of the vorinostat effect in gastric cancer patients.
Expression of ITGB5, TYMS, MYB, APOC1, CBX5, PLA2G2A, and
KIF20A which is up-regulated in human gastric cancer tissues, was
significantly decreased by vorinostat. Some of these genes are
already known to play a role in carcinogenesis or metastasis of
gastric cancer or other cancers. First, expression levels of TYMS
regulating DNA synthesis and repair showed negative relation to
drug sensitivity in gastric cancer and is a marker for drug
resistance [40]. Second, MYB is known as a proto-oncogene for
leukemia, colon cancer, breast cancer, and esophageal cancer [41–
44], and our results show for the first time that the expression of
this gene is also increased in gastric cancer. Third, APOC1
commonly up regulated in gastric cancer compared to normal
gastric epithelium [45,46], is already considered as a possible
biomarker for gastric cancer. Last, KIF20A plays a role in
cytokinesis and inhibiting expression of this gene attenuated
growth of pancreatic cancer cells [47]. In contrast, vorinostat
treatment also increased the expression of genes which are
normally low in human gastric cancer tissue, such as SCGB2A1,
Table 3. Reversed genes* after vorinostat treatment in AGS
and KATO-III among gastric cancer specific genes**.
Gene symbol Description
5 Up regulation after vorinostat treatment
SCGB2A1 secretoglobin, family 2A, member 1
TCN1 transcobalamin I (vitamin B12 binding protein, R binder family)
CFD complement factor D
APLP1 amyloid beta (A4) precursor-like protein 1
NQO1 NAD(P)H dehydrogenase, quinone 1
7 Down regulation after vorinostat treatment
ITGB5 integrin, beta 5
TYMS thymidylate synthetase
MYB v-myb myeloblastosis viral oncogene homolog
APOC1 apolipoprotein C-I
CBX5 chromobox homolog 5 (HP1 alpha homolog, Drosophila)
PLA2G2A phospholipase A2, group IIA
KIF20A kinesin family member 20A
*More than 2 fold changed genes were selected.
**Gastric cancer specific genes were extracted from GSE13861 data (3360
genes) and GSE13911 data (3242 genes).
doi:10.1371/journal.pone.0024662.t003
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TCN1, CFD, APLP1, and NQO1. CFD, known to be important in
immune defense in tissue [48], possibly participates in inflamma-
tion of gastric epithelium [49]. APLP1, a transcriptional target of
p53, may be involved in cell death [50] and therefore vorinostat-
induced expression of APLP1 may contribute to apoptotic cell
death observed in our study. NQO1 inactivation has been
associated with increased susceptibility to a variety of carcinogens
[51], and has been related to the risk of colorectal cancer [52,53].
Further experiments are required to understand the functions of
these genes and their relation to the effects of vorinostat (i.e.
induction of autophagy and cell death) in gastric cancer. However,
they are feasible to be considered as predictive biomarkers for
vorinostat sensitivity. One of the clinical implications of this ‘12
gene signature’ is that it can be used to select gastric cancer
patients who may benefit from this treatment.
In summary, we generated a global human gastric cancer gene
signature and by using Connectivity Map we found that the
HDAC inhibitor vorinostat is a strong candidate therapeutic agent
for gastric cancer. We presented that gene signature analysis may
be useful in discovering therapeutic agents for the treatment of
gastric cancer, such as vorinostat, which may be a promising
therapeutic agent alone or in combination with autophagy
inhibitors.
Supporting Information
Figure S1 Gene expression signature (3,360 genes) of
human gastric cancer. Measured gene expression values were
log 2-transformed and median-centered across samples before
generating the heatmap. The data are presented in matrix format
in which rows represent individual gene and columns represent
each tissue. The red and green color in cells reflects relative high
and low expression levels respectively.
(TIF)
Table S1 A list of 500 up regulated and 500 down
regulated genes in gastric cancer, used as input query
into Connectivity Map.
(XLS)
Table S2 A list of 80 autophagy-related genes (149
probes), used for supervised analysis (Figure 2B).
(XLS)
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